生物制药公司劲方医药(2595.HK)今日起至下周二(9月16日)招股，发售7760万股H股，香港公开发售占10%，其余为国际配售，每股招股价20.39港元，集资最多15.82亿港元。一手200股，入场费4119.13港元。该股预期9月19日挂牌。中信证券为独家保荐人。 公司拟将所得款项净额中，约33%用于核心产品GFH925的临床开发提供资金；约38%用于核心产品GFH375的临床开发提供资金；约19%用于管线中其他候选产品的进一步开发提供资金；及约10%用作营运资金及其他一般企业用途。
生物制药公司劲方医药(2595.HK)今日起至下周二(9月16日)招股，发售7760万股H股，香港公开发售占10%，其余为国际配售，每股招股价20.39港元，集资最多15.82亿港元。一手200股，入场费4119.13港元。该股预期9月19日挂牌。中信证券为独家保荐人。 公司拟将所得款项净额中，约33%用于核心产品GFH925的临床开发提供资金；约38%用于核心产品GFH375的临床开发提供资金；约19%用于管线中其他候选产品的进一步开发提供资金；及约10%用作营运资金及其他一般企业用途。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.